Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Bellevue, Washington

CNS medication trials in Bellevue, WA

26 CNS medication studies are recruiting participants at sites in Bellevue as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Bellevue at a glance

Depression studies recruiting in Bellevue

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07412756 · updated
  2. Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT05850689 · updated
  3. Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

    • Phase 3
    • Ages 10 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT06372964 · updated
  4. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07573176 · updated
  5. A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07716098 · updated
  6. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07775300 · updated
  7. A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07610473 · updated
  8. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07300969 · updated
  9. Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06830044 · updated
  10. A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Northwest Clinical Research Center /ID# 272847
    Registry record
    NCT06696755 · updated
  11. Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    LB Pharmaceuticals Inc.
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07494305 · updated
  12. A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    AbbVie
    Study site
    Northwest Clinical Research Center /ID# 277484
    Registry record
    NCT07276997 · updated
  13. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #143
    Registry record
    NCT06633016 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Bellevue, WA on ClinicalTrials.gov.

Schizophrenia studies recruiting in Bellevue

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    • Phase 3
    • Ages 5 to 17
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT06229210 · updated
  3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT06540833 · updated
  4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT06585787 · updated
  5. A Study of Brenipatide in Adult Participants With Schizophrenia

    • Phase 2
    • Ages 18 to 55
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07410507 · updated
  6. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07114874 · updated
  7. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07227818 · updated
  8. Randomized Withdrawal Study in Patients With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06961968 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Bellevue, WA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Bellevue

  1. A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT07286175 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Bellevue, WA on ClinicalTrials.gov.

ADHD studies recruiting in Bellevue

  1. A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Alkermes, Inc.
    Study site
    Alkermes Investigational Site
    Registry record
    NCT07755410 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Bellevue, WA on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Bellevue

  1. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    • Phase 2/3
    • Ages 40 to 80
    • All sexes
    Sponsor
    Biohaven Therapeutics Ltd.
    Registry record
    NCT06976268 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Bellevue, WA on ClinicalTrials.gov.

Migraine studies recruiting in Bellevue

  1. Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT04649242 · updated
  2. Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    Northwest Clinical Research Center
    Registry record
    NCT04743141 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Bellevue, WA on ClinicalTrials.gov.

Ask about studies near Bellevue

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Washington

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call